A multicenter prospective study to determine the optimal range of lymph node dissection in pancreatic cancer surgery after neoadjuvant chemotherapy
Not Applicable
- Conditions
- Pancreatic invasive ductal adenocarcinoma
- Registration Number
- JPRN-UMIN000051879
- Lead Sponsor
- niversity of Toyama
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 545
Inclusion Criteria
Not provided
Exclusion Criteria
#Active synchronous cancers #Severe complication #Inability to safely perform protocol surgery #Pretreatment other than protocol neoadjuvant chemotherapy #Pregnant, lactating woman or possible pregnancy #Psychiatric illness that interferes with daily life
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of metastases in each lymph node in the standard NAC cohort patients who met the primary analysis criteria.
- Secondary Outcome Measures
Name Time Method -The index of lymph node dissection in each lymph node in the standard NAC cohort patients who met the primary analysis criteria (percentage of lymph node metastasis x 3-year recurrence free survival, or percentage of lymph node metastasis x 5-year recurrence free survival). -1,2,3,4,5-year recurrence-free survival rate and overall survival rate, recurrence-free survival , overall survival, disease-specific survival, disease-specific survival rate, postoperative complications, site of recurrence. -Percentage of metastases in each lymph node, and the index of lymph node dissection (percentage of lymph node metastasis x 3-year recurrence free survival, or percentage of lymph node metastasis x 5-year recurrence free survival) in each lymph node about non-standard cohort patients or in standard NAC cohort patients who did not meet the primary analysis criteria.